Report Cover

Global Immuno-oncology Therapy Market 2021 by Company, Regions, Type and Application, Forecast to 2026


The Immuno-oncology Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Immuno-oncology Therapy size is estimated to be USD 1501.8 million in 2026 from USD 1268.7 million in 2020, with a change XX% between 2020 and 2021. The global Immuno-oncology Therapy market size is expected to grow at a CAGR of 4.3% for the next five years.

Market segmentation
Immuno-oncology Therapy market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
    Monoclonal Antibodies
    Immune Checkpoint Inhibitors
    Immune System Modulators
    Cancer Vaccines

Market segment by Application, can be divided into
    Hospitals
    Ambulatory Surgical Center
    Others

Market segment by players, this report covers
    Amgen
    AstraZeneca
    Bristol-Myers Squibb
    Eli-Lilly
    Roche
    GlaxoSmithKline
    Janssen Biotech
    Merck
    Novartis
    Pfizer
    Sanofi
    Spectrum Pharmaceuticals
    Takeda
    BioNTech SE
    Allogene Therapeutics
    IMAB-I-Mab Biopharma Co., Ltd.
    Arcus Biosciences
    Gritstone Oncology
    Autolus Therapeutics
    Rubius Therapeutics

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
    South America (Brazil, Argentina, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Immuno-oncology Therapy product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Immuno-oncology Therapy, with revenue, gross margin and global market share of Immuno-oncology Therapy from 2019 to 2021.
Chapter 3, the Immuno-oncology Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Immuno-oncology Therapy market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Immuno-oncology Therapy research findings and conclusion, appendix and data source.
1 Market Overview
    1.1 Product Overview and Scope of Immuno-oncology Therapy
    1.2 Classification of Immuno-oncology Therapy by Type
        1.2.1 Overview: Global Immuno-oncology Therapy Market Size by Type: 2020 Versus 2021 Versus 2026
        1.2.2 Global Immuno-oncology Therapy Revenue Market Share by Type in 2020
        1.2.3 Monoclonal Antibodies
        1.2.4 Immune Checkpoint Inhibitors
        1.2.5 Immune System Modulators
        1.2.6 Cancer Vaccines
    1.3 Global Immuno-oncology Therapy Market by Application
        1.3.1 Overview: Global Immuno-oncology Therapy Market Size by Application: 2020 Versus 2021 Versus 2026
        1.3.2 Hospitals
        1.3.3 Ambulatory Surgical Center
        1.3.4 Others
    1.4 Global Immuno-oncology Therapy Market Size & Forecast
    1.5 Global Immuno-oncology Therapy Market Size and Forecast by Region
        1.5.1 Global Immuno-oncology Therapy Market Size by Region: 2016 VS 2021 VS 2026
        1.5.2 Global Immuno-oncology Therapy Market Size by Region, (2016-2021)
        1.5.3 North America Immuno-oncology Therapy Market Size and Prospect (2016-2026)
        1.5.4 Europe Immuno-oncology Therapy Market Size and Prospect (2016-2026)
        1.5.5 Asia-Pacific Immuno-oncology Therapy Market Size and Prospect (2016-2026)
        1.5.6 South America Immuno-oncology Therapy Market Size and Prospect (2016-2026)
        1.5.7 Middle East and Africa Immuno-oncology Therapy Market Size and Prospect (2016-2026)
    1.6 Market Drivers, Restraints and Trends
        1.6.1 Immuno-oncology Therapy Market Drivers
        1.6.2 Immuno-oncology Therapy Market Restraints
        1.6.3 Immuno-oncology Therapy Trends Analysis
2 Company Profiles
    2.1 Amgen
        2.1.1 Amgen Details
        2.1.2 Amgen Major Business
        2.1.3 Amgen Immuno-oncology Therapy Product and Solutions
        2.1.4 Amgen Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.1.5 Amgen Recent Developments and Future Plans
    2.2 AstraZeneca
        2.2.1 AstraZeneca Details
        2.2.2 AstraZeneca Major Business
        2.2.3 AstraZeneca Immuno-oncology Therapy Product and Solutions
        2.2.4 AstraZeneca Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.2.5 AstraZeneca Recent Developments and Future Plans
    2.3 Bristol-Myers Squibb
        2.3.1 Bristol-Myers Squibb Details
        2.3.2 Bristol-Myers Squibb Major Business
        2.3.3 Bristol-Myers Squibb Immuno-oncology Therapy Product and Solutions
        2.3.4 Bristol-Myers Squibb Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans
    2.4 Eli-Lilly
        2.4.1 Eli-Lilly Details
        2.4.2 Eli-Lilly Major Business
        2.4.3 Eli-Lilly Immuno-oncology Therapy Product and Solutions
        2.4.4 Eli-Lilly Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.4.5 Eli-Lilly Recent Developments and Future Plans
    2.5 Roche
        2.5.1 Roche Details
        2.5.2 Roche Major Business
        2.5.3 Roche Immuno-oncology Therapy Product and Solutions
        2.5.4 Roche Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.5.5 Roche Recent Developments and Future Plans
    2.6 GlaxoSmithKline
        2.6.1 GlaxoSmithKline Details
        2.6.2 GlaxoSmithKline Major Business
        2.6.3 GlaxoSmithKline Immuno-oncology Therapy Product and Solutions
        2.6.4 GlaxoSmithKline Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.6.5 GlaxoSmithKline Recent Developments and Future Plans
    2.7 Janssen Biotech
        2.7.1 Janssen Biotech Details
        2.7.2 Janssen Biotech Major Business
        2.7.3 Janssen Biotech Immuno-oncology Therapy Product and Solutions
        2.7.4 Janssen Biotech Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.7.5 Janssen Biotech Recent Developments and Future Plans
    2.8 Merck
        2.8.1 Merck Details
        2.8.2 Merck Major Business
        2.8.3 Merck Immuno-oncology Therapy Product and Solutions
        2.8.4 Merck Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.8.5 Merck Recent Developments and Future Plans
    2.9 Novartis
        2.9.1 Novartis Details
        2.9.2 Novartis Major Business
        2.9.3 Novartis Immuno-oncology Therapy Product and Solutions
        2.9.4 Novartis Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.9.5 Novartis Recent Developments and Future Plans
    2.10 Pfizer 
        2.10.1 Pfizer Details
        2.10.2 Pfizer Major Business
        2.10.3 Pfizer Immuno-oncology Therapy Product and Solutions
        2.10.4 Pfizer Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.10.5 Pfizer Recent Developments and Future Plans
    2.11 Sanofi
        2.11.1 Sanofi Details
        2.11.2 Sanofi Major Business
        2.11.3 Sanofi Immuno-oncology Therapy Product and Solutions
        2.11.4 Sanofi Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.11.5 Sanofi Recent Developments and Future Plans
    2.12 Spectrum Pharmaceuticals
        2.12.1 Spectrum Pharmaceuticals Details
        2.12.2 Spectrum Pharmaceuticals Major Business
        2.12.3 Spectrum Pharmaceuticals Immuno-oncology Therapy Product and Solutions
        2.12.4 Spectrum Pharmaceuticals Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.12.5 Spectrum Pharmaceuticals Recent Developments and Future Plans
    2.13 Takeda
        2.13.1 Takeda Details
        2.13.2 Takeda Major Business
        2.13.3 Takeda Immuno-oncology Therapy Product and Solutions
        2.13.4 Takeda Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.13.5 Takeda Recent Developments and Future Plans
    2.14 BioNTech SE
        2.14.1 BioNTech SE Details
        2.14.2 BioNTech SE Major Business
        2.14.3 BioNTech SE Immuno-oncology Therapy Product and Solutions
        2.14.4 BioNTech SE Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.14.5 BioNTech SE Recent Developments and Future Plans
    2.15 Allogene Therapeutics
        2.15.1 Allogene Therapeutics Details
        2.15.2 Allogene Therapeutics Major Business
        2.15.3 Allogene Therapeutics Immuno-oncology Therapy Product and Solutions
        2.15.4 Allogene Therapeutics Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.15.5 Allogene Therapeutics Recent Developments and Future Plans
    2.16 IMAB-I-Mab Biopharma Co., Ltd.
        2.16.1 IMAB-I-Mab Biopharma Co., Ltd. Details
        2.16.2 IMAB-I-Mab Biopharma Co., Ltd. Major Business
        2.16.3 IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Product and Solutions
        2.16.4 IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.16.5 IMAB-I-Mab Biopharma Co., Ltd. Recent Developments and Future Plans
    2.17 Arcus Biosciences
        2.17.1 Arcus Biosciences Details
        2.17.2 Arcus Biosciences Major Business
        2.17.3 Arcus Biosciences Immuno-oncology Therapy Product and Solutions
        2.17.4 Arcus Biosciences Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.17.5 Arcus Biosciences Recent Developments and Future Plans
    2.18 Gritstone Oncology
        2.18.1 Gritstone Oncology Details
        2.18.2 Gritstone Oncology Major Business
        2.18.3 Gritstone Oncology Immuno-oncology Therapy Product and Solutions
        2.18.4 Gritstone Oncology Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.18.5 Gritstone Oncology Recent Developments and Future Plans
    2.19 Autolus Therapeutics
        2.19.1 Autolus Therapeutics Details
        2.19.2 Autolus Therapeutics Major Business
        2.19.3 Autolus Therapeutics Immuno-oncology Therapy Product and Solutions
        2.19.4 Autolus Therapeutics Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.19.5 Autolus Therapeutics Recent Developments and Future Plans
    2.20 Rubius Therapeutics
        2.20.1 Rubius Therapeutics Details
        2.20.2 Rubius Therapeutics Major Business
        2.20.3 Rubius Therapeutics Immuno-oncology Therapy Product and Solutions
        2.20.4 Rubius Therapeutics Immuno-oncology Therapy Revenue, Gross Margin and Market Share (2019-2021)
        2.20.5 Rubius Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
    3.1 Global Immuno-oncology Therapy Revenue and Share by Players (2019-2021)
    3.2 Market Concentration Rate
        3.2.1 Top 3 Immuno-oncology Therapy Players Market Share
        3.2.2 Top 10 Immuno-oncology Therapy Players Market Share
        3.2.3 Market Competition Trend
    3.3 Immuno-oncology Therapy Players Head Office, Products and Services Provided
    3.4 Mergers & Acquisitions
    3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
    4.1 Global Immuno-oncology Therapy Revenue and Market Share by Type (2016-2021)
    4.2 Global Immuno-oncology Therapy Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
    5.1 Global Immuno-oncology Therapy Revenue Market Share by Application (2016-2021)
    5.2 Immuno-oncology Therapy Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
    6.1 North America Immuno-oncology Therapy Revenue by Type (2016-2026)
    6.2 North America Immuno-oncology Therapy Revenue by Application (2016-2026)
    6.3 North America Immuno-oncology Therapy Market Size by Country
        6.3.1 North America Immuno-oncology Therapy Revenue by Country (2016-2026)
        6.3.2 United States Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        6.3.3 Canada Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        6.3.4 Mexico Immuno-oncology Therapy Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
    7.1 Europe Immuno-oncology Therapy Revenue by Type (2016-2026)
    7.2 Europe Immuno-oncology Therapy Revenue by Application (2016-2026)
    7.3 Europe Immuno-oncology Therapy Market Size by Country
        7.3.1 Europe Immuno-oncology Therapy Revenue by Country (2016-2026)
        7.3.2 Germany Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        7.3.3 France Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        7.3.4 United Kingdom Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        7.3.5 Russia Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        7.3.6 Italy Immuno-oncology Therapy Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
    8.1 Asia-Pacific Immuno-oncology Therapy Revenue by Type (2016-2026)
    8.2 Asia-Pacific Immuno-oncology Therapy Revenue by Application (2016-2026)
    8.3 Asia-Pacific Immuno-oncology Therapy Market Size by Region
        8.3.1 Asia-Pacific Immuno-oncology Therapy Revenue by Region (2016-2026)
        8.3.2 China Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        8.3.3 Japan Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        8.3.4 South Korea Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        8.3.5 India Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        8.3.6 Southeast Asia Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        8.3.7 Australia Immuno-oncology Therapy Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
    9.1 South America Immuno-oncology Therapy Revenue by Type (2016-2026)
    9.2 South America Immuno-oncology Therapy Revenue by Application (2016-2026)
    9.3 South America Immuno-oncology Therapy Market Size by Country
        9.3.1 South America Immuno-oncology Therapy Revenue by Country (2016-2026)
        9.3.2 Brazil Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        9.3.3 Argentina Immuno-oncology Therapy Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
    10.1 Middle East & Africa Immuno-oncology Therapy Revenue by Type (2016-2026)
    10.2 Middle East & Africa Immuno-oncology Therapy Revenue by Application (2016-2026)
    10.3 Middle East & Africa Immuno-oncology Therapy Market Size by Country
        10.3.1 Middle East & Africa Immuno-oncology Therapy Revenue by Country (2016-2026)
        10.3.2 Turkey Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        10.3.3 Saudi Arabia Immuno-oncology Therapy Market Size and Forecast (2016-2026)
        10.3.4 UAE Immuno-oncology Therapy Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
    12.1 Methodology
    12.2 Research Process and Data Source
    12.3 Disclaimer

List of Tables Table 1. Global Immuno-oncology Therapy Revenue by Type, (USD Million), 2020 VS 2021 VS 2026 Table 2. Global Immuno-oncology Therapy Revenue by Application, (USD Million), 2020 VS 2021 VS 2026 Table 3. Global Market Immuno-oncology Therapy Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026) Table 4. Global Immuno-oncology Therapy Revenue (USD Million) by Region (2016-2021) Table 5. Global Immuno-oncology Therapy Revenue Market Share by Region (2021-2026) Table 6. Amgen Corporate Information, Head Office, and Major Competitors Table 7. Amgen Major Business Table 8. Amgen Immuno-oncology Therapy Product and Solutions Table 9. Amgen Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 10. AstraZeneca Corporate Information, Head Office, and Major Competitors Table 11. AstraZeneca Major Business Table 12. AstraZeneca Immuno-oncology Therapy Product and Solutions Table 13. AstraZeneca Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 14. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors Table 15. Bristol-Myers Squibb Major Business Table 16. Bristol-Myers Squibb Immuno-oncology Therapy Product and Solutions Table 17. Bristol-Myers Squibb Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 18. Eli-Lilly Corporate Information, Head Office, and Major Competitors Table 19. Eli-Lilly Major Business Table 20. Eli-Lilly Immuno-oncology Therapy Product and Solutions Table 21. Eli-Lilly Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 22. Roche Corporate Information, Head Office, and Major Competitors Table 23. Roche Major Business Table 24. Roche Immuno-oncology Therapy Product and Solutions Table 25. Roche Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 26. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors Table 27. GlaxoSmithKline Major Business Table 28. GlaxoSmithKline Immuno-oncology Therapy Product and Solutions Table 29. GlaxoSmithKline Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 30. Janssen Biotech Corporate Information, Head Office, and Major Competitors Table 31. Janssen Biotech Major Business Table 32. Janssen Biotech Immuno-oncology Therapy Product and Solutions Table 33. Janssen Biotech Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 34. Merck Corporate Information, Head Office, and Major Competitors Table 35. Merck Major Business Table 36. Merck Immuno-oncology Therapy Product and Solutions Table 37. Merck Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 38. Novartis Corporate Information, Head Office, and Major Competitors Table 39. Novartis Major Business Table 40. Novartis Immuno-oncology Therapy Product and Solutions Table 41. Novartis Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 42. Pfizer Corporate Information, Head Office, and Major Competitors Table 43. Pfizer Major Business Table 44. Pfizer Immuno-oncology Therapy Product and Solutions Table 45. Pfizer Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 46. Sanofi Corporate Information, Head Office, and Major Competitors Table 47. Sanofi Major Business Table 48. Sanofi Immuno-oncology Therapy Product and Solutions Table 49. Sanofi Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 50. Spectrum Pharmaceuticals Corporate Information, Head Office, and Major Competitors Table 51. Spectrum Pharmaceuticals Major Business Table 52. Spectrum Pharmaceuticals Immuno-oncology Therapy Product and Solutions Table 53. Spectrum Pharmaceuticals Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 54. Takeda Corporate Information, Head Office, and Major Competitors Table 55. Takeda Major Business Table 56. Takeda Immuno-oncology Therapy Product and Solutions Table 57. Takeda Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 58. BioNTech SE Corporate Information, Head Office, and Major Competitors Table 59. BioNTech SE Major Business Table 60. BioNTech SE Immuno-oncology Therapy Product and Solutions Table 61. BioNTech SE Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 62. Allogene Therapeutics Corporate Information, Head Office, and Major Competitors Table 63. Allogene Therapeutics Major Business Table 64. Allogene Therapeutics Immuno-oncology Therapy Product and Solutions Table 65. Allogene Therapeutics Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 66. IMAB-I-Mab Biopharma Co., Ltd. Corporate Information, Head Office, and Major Competitors Table 67. IMAB-I-Mab Biopharma Co., Ltd. Major Business Table 68. IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Product and Solutions Table 69. IMAB-I-Mab Biopharma Co., Ltd. Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 70. Arcus Biosciences Corporate Information, Head Office, and Major Competitors Table 71. Arcus Biosciences Major Business Table 72. Arcus Biosciences Immuno-oncology Therapy Product and Solutions Table 73. Arcus Biosciences Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 74. Gritstone Oncology Corporate Information, Head Office, and Major Competitors Table 75. Gritstone Oncology Major Business Table 76. Gritstone Oncology Immuno-oncology Therapy Product and Solutions Table 77. Gritstone Oncology Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 78. Autolus Therapeutics Corporate Information, Head Office, and Major Competitors Table 79. Autolus Therapeutics Major Business Table 80. Autolus Therapeutics Immuno-oncology Therapy Product and Solutions Table 81. Autolus Therapeutics Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 82. Rubius Therapeutics Corporate Information, Head Office, and Major Competitors Table 83. Rubius Therapeutics Major Business Table 84. Rubius Therapeutics Immuno-oncology Therapy Product and Solutions Table 85. Rubius Therapeutics Immuno-oncology Therapy Revenue (USD Million), Gross Margin and Market Share (2019-2021) Table 86. Global Immuno-oncology Therapy Revenue (USD Million) by Players (2019-2021) Table 87. Global Immuno-oncology Therapy Revenue Share by Players (2019-2021) Table 88. Breakdown of Immuno-oncology Therapy by Company Type (Tier 1, Tier 2 and Tier 3) Table 89. Immuno-oncology Therapy Players Head Office, Products and Services Provided Table 90. Immuno-oncology Therapy Mergers & Acquisitions in the Past Five Years Table 91. Immuno-oncology Therapy New Entrants and Expansion Plans Table 92. Global Immuno-oncology Therapy Revenue (USD Million) by Type (2016-2021) Table 93. Global Immuno-oncology Therapy Revenue Share by Type (2016-2021) Table 94. Global Immuno-oncology Therapy Revenue Forecast by Type (2021-2026) Table 95. Global Immuno-oncology Therapy Revenue by Application (2016-2021) Table 96. Global Immuno-oncology Therapy Revenue Forecast by Application (2021-2026) Table 97. North America Immuno-oncology Therapy Revenue by Type (2016-2021) & (USD Million) Table 98. North America Immuno-oncology Therapy Revenue by Type (2021-2026) & (USD Million) Table 99. North America Immuno-oncology Therapy Revenue by Application (2016-2021) & (USD Million) Table 100. North America Immuno-oncology Therapy Revenue by Application (2021-2026) & (USD Million) Table 101. North America Immuno-oncology Therapy Revenue by Country (2016-2021) & (USD Million) Table 102. North America Immuno-oncology Therapy Revenue by Country (2021-2026) & (USD Million) Table 103. Europe Immuno-oncology Therapy Revenue by Type (2016-2021) & (USD Million) Table 104. Europe Immuno-oncology Therapy Revenue by Type (2021-2026) & (USD Million) Table 105. Europe Immuno-oncology Therapy Revenue by Application (2016-2021) & (USD Million) Table 106. Europe Immuno-oncology Therapy Revenue by Application (2021-2026) & (USD Million) Table 107. Europe Immuno-oncology Therapy Revenue by Country (2016-2021) & (USD Million) Table 108. Europe Immuno-oncology Therapy Revenue by Country (2021-2026) & (USD Million) Table 109. Asia-Pacific Immuno-oncology Therapy Revenue by Type (2016-2021) & (USD Million) Table 110. Asia-Pacific Immuno-oncology Therapy Revenue by Type (2021-2026) & (USD Million) Table 111. Asia-Pacific Immuno-oncology Therapy Revenue by Application (2016-2021) & (USD Million) Table 112. Asia-Pacific Immuno-oncology Therapy Revenue by Application (2021-2026) & (USD Million) Table 113. Asia-Pacific Immuno-oncology Therapy Revenue by Region (2016-2021) & (USD Million) Table 114. Asia-Pacific Immuno-oncology Therapy Revenue by Region (2021-2026) & (USD Million) Table 115. South America Immuno-oncology Therapy Revenue by Type (2016-2021) & (USD Million) Table 116. South America Immuno-oncology Therapy Revenue by Type (2021-2026) & (USD Million) Table 117. South America Immuno-oncology Therapy Revenue by Application (2016-2021) & (USD Million) Table 118. South America Immuno-oncology Therapy Revenue by Application (2021-2026) & (USD Million) Table 119. South America Immuno-oncology Therapy Revenue by Country (2016-2021) & (USD Million) Table 120. South America Immuno-oncology Therapy Revenue by Country (2021-2026) & (USD Million) Table 121. Middle East & Africa Immuno-oncology Therapy Revenue by Type (2016-2021) & (USD Million) Table 122. Middle East & Africa Immuno-oncology Therapy Revenue by Type (2021-2026) & (USD Million) Table 123. Middle East & Africa Immuno-oncology Therapy Revenue by Application (2016-2021) & (USD Million) Table 124. Middle East & Africa Immuno-oncology Therapy Revenue by Application (2021-2026) & (USD Million) Table 125. Middle East & Africa Immuno-oncology Therapy Revenue by Country (2016-2021) & (USD Million) Table 126. Middle East & Africa Immuno-oncology Therapy Revenue by Country (2021-2026) & (USD Million) List of Figures Figure 1. Immuno-oncology Therapy Picture Figure 2. Global Immuno-oncology Therapy Revenue Market Share by Type in 2020 Figure 3. Monoclonal Antibodies Figure 4. Immune Checkpoint Inhibitors Figure 5. Immune System Modulators Figure 6. Cancer Vaccines Figure 7. Immuno-oncology Therapy Revenue Market Share by Application in 2020 Figure 8. Hospitals Picture Figure 9. Ambulatory Surgical Center Picture Figure 10. Others Picture Figure 11. Global Immuno-oncology Therapy Revenue, (USD Million): 2020 VS 2021 VS 2026 Figure 12. Global Immuno-oncology Therapy Revenue and Forecast (2016-2026) & (USD Million) Figure 13. Global Immuno-oncology Therapy Revenue Market Share by Region (2016-2026) Figure 14. Global Immuno-oncology Therapy Revenue Market Share by Region in 2020 Figure 15. North America Immuno-oncology Therapy Revenue (USD Million) and Growth Rate (2016-2026) Figure 16. Europe Immuno-oncology Therapy Revenue (USD Million) and Growth Rate (2016-2026) Figure 17. Asia-Pacific Immuno-oncology Therapy Revenue (USD Million) and Growth Rate (2016-2026) Figure 18. South America Immuno-oncology Therapy Revenue (USD Million) and Growth Rate (2016-2026) Figure 19. Middle East and Africa Immuno-oncology Therapy Revenue (USD Million) and Growth Rate (2016-2026) Figure 20. Immuno-oncology Therapy Market Drivers Figure 21. Immuno-oncology Therapy Market Restraints Figure 22. Immuno-oncology Therapy Market Trends Figure 23. Amgen Recent Developments and Future Plans Figure 24. AstraZeneca Recent Developments and Future Plans Figure 25. Bristol-Myers Squibb Recent Developments and Future Plans Figure 26. Eli-Lilly Recent Developments and Future Plans Figure 27. Roche Recent Developments and Future Plans Figure 28. GlaxoSmithKline Recent Developments and Future Plans Figure 29. Janssen Biotech Recent Developments and Future Plans Figure 30. Merck Recent Developments and Future Plans Figure 31. Novartis Recent Developments and Future Plans Figure 32. Pfizer Recent Developments and Future Plans Figure 33. Sanofi Recent Developments and Future Plans Figure 34. Spectrum Pharmaceuticals Recent Developments and Future Plans Figure 35. Takeda Recent Developments and Future Plans Figure 36. BioNTech SE Recent Developments and Future Plans Figure 37. Allogene Therapeutics Recent Developments and Future Plans Figure 38. IMAB-I-Mab Biopharma Co., Ltd. Recent Developments and Future Plans Figure 39. Arcus Biosciences Recent Developments and Future Plans Figure 40. Gritstone Oncology Recent Developments and Future Plans Figure 41. Autolus Therapeutics Recent Developments and Future Plans Figure 42. Rubius Therapeutics Recent Developments and Future Plans Figure 43. Global Immuno-oncology Therapy Revenue Share by Players in 2020 Figure 44. Immuno-oncology Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) Figure 45. Global Top 3 Players Immuno-oncology Therapy Revenue Market Share in 2020 Figure 46. Global Top 10 Players Immuno-oncology Therapy Revenue Market Share in 2020 Figure 47. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021) Figure 48. Global Immuno-oncology Therapy Revenue Share by Type in 2020 Figure 49. Global Immuno-oncology Therapy Market Share Forecast by Type (2021-2026) Figure 50. Global Immuno-oncology Therapy Revenue Share by Application in 2020 Figure 51. Global Immuno-oncology Therapy Market Share Forecast by Application (2021-2026) Figure 52. North America Immuno-oncology Therapy Sales Market Share by Type (2016-2026) Figure 53. North America Immuno-oncology Therapy Sales Market Share by Application (2016-2026) Figure 54. North America Immuno-oncology Therapy Revenue Market Share by Country (2016-2026) Figure 55. United States Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 56. Canada Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 57. Mexico Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 58. Europe Immuno-oncology Therapy Sales Market Share by Type (2016-2026) Figure 59. Europe Immuno-oncology Therapy Sales Market Share by Application (2016-2026) Figure 60. Europe Immuno-oncology Therapy Revenue Market Share by Country (2016-2026) Figure 61. Germany Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 62. France Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 63. United Kingdom Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 64. Russia Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 65. Italy Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 66. Asia-Pacific Immuno-oncology Therapy Sales Market Share by Type (2016-2026) Figure 67. Asia-Pacific Immuno-oncology Therapy Sales Market Share by Application (2016-2026) Figure 68. Asia-Pacific Immuno-oncology Therapy Revenue Market Share by Region (2016-2026) Figure 69. China Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 70. Japan Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 71. South Korea Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 72. India Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 73. Southeast Asia Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 74. Australia Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 75. South America Immuno-oncology Therapy Sales Market Share by Type (2016-2026) Figure 76. South America Immuno-oncology Therapy Sales Market Share by Application (2016-2026) Figure 77. South America Immuno-oncology Therapy Revenue Market Share by Country (2016-2026) Figure 78. Brazil Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 79. Argentina Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 80. Middle East and Africa Immuno-oncology Therapy Sales Market Share by Type (2016-2026) Figure 81. Middle East and Africa Immuno-oncology Therapy Sales Market Share by Application (2016-2026) Figure 82. Middle East and Africa Immuno-oncology Therapy Revenue Market Share by Country (2016-2026) Figure 83. Turkey Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 84. Saudi Arabia Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 85. UAE Immuno-oncology Therapy Revenue and Growth Rate (2016-2026) & (USD Million) Figure 86. Methodology Figure 87. Research Process and Data Source

Qualitative Analysis covers:

  • Industry Status and Trends
  • Manufacturer/Company profiles, manufacturing base distribution, sales areas, product introduction, main business, market position and their competitors.
  • Product Development, Technology, Price, Cost, Manufacturing Process and Trends
  • Market segment by regions, types, applications and forecast
  • Market opportunities, potential, government policies and influence factors.
     

Quantitative Analysis covers:

  • Market size (value, sales/output, historical data and forecasts)
  • Sales/output/capacity, revenue, price, gross margin, market share, for top players. Through interviewing each manufacturers,  distributors, traders, dealers and buyers etc.
  • Cost structure, proportion, price trend, gross margin and trend, status and trend, for 10 years
  • Market size by types, regions, applications for 10 years
  • Market forecast based on the potential demand from downstream clients/buyers, government, influence factors and the total economic indication, maybe occur in following years.
     

Data Sources:

Methodology

 

Publisher: GlobalInfoResearch
Chat with us